Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Proven Cytomegalovirus Colitis Associated with Dasatinib Administration in Two Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients

  • Jeong Min Kim (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Hyun Mi Kang (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • In Hyuk Yoo (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Dong-Gun Lee (Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea) ;
  • Nack-Gyun Chung (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Bin Cho (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • Received : 2023.04.19
  • Accepted : 2023.05.13
  • Published : 2023.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Gastrointestinal (GI) bleeding is a rare adverse event of dasatinib, which is known to be caused by dasatinib-induced colitis, severe thrombocytopenia, and platelet dysfunction. We present two cases of pediatric patients who developed hematochezia during treatment with dasatinib after hematopoietic stem cell transplantation (HSCT). A colonic tissue biopsy was performed to differentiate the cause of GI bleeding. Both patients were diagnosed with proven cytomegalovirus (CMV) colitis, but only one was treated with ganciclovir. The patient who did not receive antiviral therapy experienced recurrent GI bleeding during dasatinib administration, leading to multiple treatment interruptions. During dasatinib therapy after HSCT, patients with GI bleeding and confirmed CMV colitis may benefit from antiviral therapy to reduce interruptions in dasatinib therapy.

Keywords

References

  1. Yun S, Vincelette ND, Segar JM, Dong Y, Shen Y, Kim DW, et al. Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid lLeukemia across risk groups: a systematic review and meta-analysis of eight randomized trials. Clin Lymphoma Myeloma Leuk 2016;16:e85-94. https://doi.org/10.1016/j.clml.2016.03.003
  2. Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 2014;28:1467-71. https://doi.org/10.1038/leu.2014.30
  3. Keating GM. Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia. Drugs 2017;77:85-96. https://doi.org/10.1007/s40265-016-0677-x
  4. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41. https://doi.org/10.1056/NEJMoa055229
  5. Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. Clin Lymphoma Myeloma Leuk 2017;17:78-82. https://doi.org/10.1016/j.clml.2016.09.012
  6. Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer 2020;147:3160-7. https://doi.org/10.1002/ijc.33119
  7. Kmira Z, Nesrine BS, Houneida Z, Wafa BF, Aida S, Yosra BY, et al. Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use. World J Gastrointest Pathophysiol 2013;4:59-62. https://doi.org/10.4291/wjgp.v4.i3.59
  8. Schwartz JM, Wolford JL, Thornquist MD, Hockenbery DM, Murakami CS, Drennan F, et al. Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes, and outcome. Am J Gastroenterol 2001;96:385-93. https://doi.org/10.1111/j.1572-0241.2001.03549.x
  9. Tuncer HH, Rana N, Milani C, Darko A, Al-Homsi SA. Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. World J Gastroenterol 2012;18:1851-60. https://doi.org/10.3748/wjg.v18.i16.1851
  10. Kang HM, Kim SK, Ryu IH, Lee JW, Lee DG, Chung NG, et al. Clinical characteristics and viral load patterns in children with cytomegalovirus gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2021;56:2813-9. https://doi.org/10.1038/s41409-021-01394-8
  11. Torres HA, Chemaly RF. Viral infection or reactivation in patients during treatment with dasatinib: a call for screening? Leuk Lymphoma 2007;48:2308-9. https://doi.org/10.1080/10428190701760086
  12. Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011;25:1587-97. https://doi.org/10.1038/leu.2011.135
  13. Choi JK, Cho SY, Choi SM, Kim GH, Lee SE, Lee S, et al. Cytomegalovirus colitis during dasatinib treatment for patients with hematologic malignancy: case series and literature review. Infect Chemother 2018;50:153-9. https://doi.org/10.3947/ic.2018.50.2.153
  14. Yassin MA, Nashwan AJ, Soliman AT, Yousif A, Moustafa A, AlBattah A, et al. Cytomegalovirus-induced hemorrhagic colitis in a patient with chronic myeloid leukemia (chronic phase) on dasatinib as an upfront therapy. Clin Med Insights Case Rep 2015;8:77-81. https://doi.org/10.4137/CCRep.S25327
  15. Aldoss I, Gaal K, Al Malki MM, Ali H, Nakamura R, Forman SJ, et al. Dasatinib-induced colitis after allogeneic stem cell transplantation for philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2016;22:1900-3. https://doi.org/10.1016/j.bbmt.2016.06.022